

# **NEWS RELEASE**

### RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

Milan, 12<sup>th</sup> May 2025 – Within the Recordati's share buy-back program communicated to the market on 29<sup>th</sup> April 2025 and initiated on 30<sup>th</sup> April 2025, as per authorization granted by the Shareholders' Meeting held on 29<sup>th</sup> April 2025, with the object of the servicing of current stock option / performance shares plans in favour of the Recordati Group's management or share-based incentive plans that might be approved by the Company in the future, the Company communicates the following purchase transactions of Recordati shares pursuant to art. 2, paragraph 3, of the EU Delegated Regulation 2016/1052/EU, on the basis of the information provided by UBS Europe SE as intermediary in charge of executing, in full independency, the share buy-back program on behalf of the Company.

Aggregate details of daily transactions made from 5<sup>th</sup> to 9<sup>th</sup> May 2025 in Recordati ordinary shares (ISIN IT0003828271) are as follows:

SUMMARY OF PURCHASE TRANSACTIONS							
Date	Type of Transaction	Quantity	Weighted average price (Euro)	Exchange			
09/05/2025	Purchase	2,329	52.5512	MTA			
TOTAL		2,329	52.5512				

The details of all the purchase transactions carried out in the period indicated above are reported in the following pages.

On 9<sup>th</sup> May 2025, the Company held no. 3,136,086 treasury shares which amount to 1.500% of the current share capital.

**Recordati** is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,580 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.

#### RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office Via Matteo Civitali, 1 20148 Milano, Italy Tel. +39 02 487871 Fax +39 02 40073747 www.recordati.com

Share Capital € 26.140.644,50 fully paid-up Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150 Tax Code/VAT No. 00748210150 Milano R.E.A. No. 401832



#### **Investor Relations**

Eugenia Litz Gianluca Saletta +44 7824 394 750 +39 348 979 4876

 $\underline{investorelations@recordati.it} \\ \underline{investorelations@recordati.it}$ 

#### **Media Relations**

ICR Healthcare US: UK, Europe & Rest of World:

Alexis Feinberg Jessica Hodgson +1 203 939 2225 +44 7561 424 788

recordatiuspr@westwicke.com recordati@consilium-comms.com



## Attachment: daily details of transactions

Date	Time (GMT)	Currency	Exchange	Price	Quantity
09/05/2025	08:28:25	EUR	MTA	52,5000	132
09/05/2025	08:33:26	EUR	MTA	52,9500	96
09/05/2025	08:55:11	EUR	MTA	52,8000	126
09/05/2025	09:57:25	EUR	MTA	52,4500	145
09/05/2025	10:05:58	EUR	MTA	52,7000	106
09/05/2025	10:05:58	EUR	MTA	52,7000	130
09/05/2025	12:16:10	EUR	MTA	52,7500	100
09/05/2025	12:16:51	EUR	MTA	52,7500	9
09/05/2025	12:16:51	EUR	MTA	52,7500	9
09/05/2025	12:26:36	EUR	MTA	52,6500	111
09/05/2025	14:06:44	EUR	MTA	52,8000	139
09/05/2025	14:20:34	EUR	MTA	52,6500	117
09/05/2025	15:18:13	EUR	MTA	52,5000	145
09/05/2025	15:18:13	EUR	MTA	52,5000	126
09/05/2025	15:18:13	EUR	MTA	52,5000	121
09/05/2025	15:18:13	EUR	MTA	52,5000	146
09/05/2025	15:38:43	EUR	MTA	52,3500	60
09/05/2025	16:08:25	EUR	MTA	52,3500	120
09/05/2025	16:08:25	EUR	MTA	52,3500	147
09/05/2025	16:08:25	EUR	MTA	52,3500	101